SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.

NCT05351788 | Recruiting Phase 2

• 1 other identifier: SKB264-Ⅱ-05
• Study Type: interventional
• Target: 110
• Locations: 1 country
• Sites: 2

Brief Summary

The purpose of this study is to assess the safety, tolerability and preliminary antitumor activity of SKB264 in combination with KL-A167 with or without chemotherapy with advanced or metastatic non-small cell lung cancer. The study is divided into two parts. Part 1 will be the safety run-in phase, and Part 2 will be the cohort expansion phase.

Conditions

Non-small Cell Lung Cancer

Outcome Measures

Primary Outcomes (2)

• Incidence and severity of adverse events (AEs)

  Incidence and severity of adverse events (AEs) graded by Common Terminology Criteria for Adverse Events (CTCAE) v5.0

  From baseline up to 30 days after last dose or to the beginning of the new anti-cancer therapy, up to 24 months

• Objective Response Rate (ORR)

  Objective Response Rate (ORR) is the percentage of participants who achieved a best overall response of Complete Response (CR) or Partial Response (PR), assessed by Investigator based on RECIST version 1.1.

  From baseline to first documented objective response, up to 24 months

Secondary Outcomes (8)

• Progression-free survival (PFS)

  From baseline to the first documented disease progression or date of death (whichever occurs first), up to 24 months

• Duration of response (DOR)

  From the date of first objective response (CR or PR) to the date of first documentation of PD or death (whichever occurs first), up to 24 months

• Disease control rate (DCR)

  From baseline to date of first documented objective response (CR, PR, and SD), up to 24 months

• Pharmacokinetic Parameter Maximum Plasma Concentration (Cmax) of SKB264-ADC, SKB264-TAB and free KL610023

  Cycle 1-8, every 4 cycles starting from Cycle 12 Day 1: pre-dose, post-dose (each cycle is 21 days), up to 24 months

• Pharmacokinetic Parameter Minimum Plasma Concentration (Cmin) of SKB264-ADC, SKB264-TAB and free KL610023

  Cycle 1-8, every 4 cycles starting from Cycle 12 Day 1: pre-dose, post-dose (each cycle is 21 days), up to 24 months

Study Arms (3)

SKB264+KL-A167

EXPERIMENTAL

Participants received SKB264 followed by KL-A167

Drug: SKB264; Drug: KL-A167

SKB264+KL-A167+ Carboplatin or Cisplatin (EGFR wide type)

EXPERIMENTAL

Participants received SKB264 followed by KL-A167 with Carboplatin or Cisplatin

Drug: SKB264; Drug: KL-A167; Drug: Carboplatin; Drug: Cisplatin

SKB264+KL-A167+ Carboplatin or Cisplatin (EGFR mutation)

EXPERIMENTAL

Participants received SKB264 followed by KL-A167 with Carboplatin or Cisplatin

Drug: SKB264; Drug: KL-A167; Drug: Carboplatin; Drug: Cisplatin

Interventions

SKB264 DRUG

SKB264 will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (5mg/kg)

SKB264+KL-A167; SKB264+KL-A167+ Carboplatin or Cisplatin (EGFR mutation); SKB264+KL-A167+ Carboplatin or Cisplatin (EGFR wide type)

KL-A167 DRUG

KL-A167 will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (1200mg Q3W)

SKB264+KL-A167; SKB264+KL-A167+ Carboplatin or Cisplatin (EGFR mutation); SKB264+KL-A167+ Carboplatin or Cisplatin (EGFR wide type)

Carboplatin DRUG

Carboplatin will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle（AUC 5)

SKB264+KL-A167+ Carboplatin or Cisplatin (EGFR mutation); SKB264+KL-A167+ Carboplatin or Cisplatin (EGFR wide type)

Cisplatin DRUG

Cisplatin will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (75mg/m²)

SKB264+KL-A167+ Carboplatin or Cisplatin (EGFR mutation); SKB264+KL-A167+ Carboplatin or Cisplatin (EGFR wide type)

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Males or females ≥ 18 and ≤ 75 years of age at the time of signing the informed consent form;
• Histologically and cytologically confirmed NSCLC;
• Cohort 1: Patients with locally advanced/metastatic NSCLC with wild-type EGFR and negative ALK fusion gene, no or at most one prior line of systemic chemotherapy regimen for advanced or metastatic NSCLC. Cohort 2: Patients with locally advanced/metastatic NSCLC with wild-type EGFR and negative ALK fusion gene, no prior systemic therapy. Cohort 3: Patients with locally advanced/metastatic NSCLC with EGFR activating mutation and negative ALK fusion gene, who have failed previous treatment with EGFR-TKIs.
• Provide fresh or archival tumor tissue for biomarker testing and analysis;
• Patients with at least one measurable lesion per RECIST v1.1 criteria, and patients with only skin or bone lesions cannot be enrolled;
• Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 with an expected survival of ≥ 12 weeks;
• Adequate organ and bone marrow function
• For female patients of childbearing age and male patients with partners of childbearing age, they must use effective medical contraception during the study treatment period and for 6 months after the last dose of study medication (see Annex for specific contraceptive measures);
• Each patient must voluntarily agree to participate in the study, sign the informed consent form, and comply with the protocol-specified visits and relevant procedures.

You may not qualify if:

• Presence of small cell lung carcinoma (SCLC) components in histological pathology;
• History of other malignancies;
• Presence of metastases to brainstem, meninges and spinal cord, or spinal cord compression;
• Presence of active central nervous system (CNS) metastases;
• Imaging (CT or MRI) shows that the tumor surrounds important blood vessels, or the investigator determines that the tumor is most likely to invade important blood vessels during the subsequent study to cause fatal major hemorrhage;
• Serious or uncontrolled cardiac disease or clinical symptoms requiring treatment, including any of the following:
• Patients with (noninfectious) interstitial lung disease (ILD) or history of pneumonia requiring steroid therapy; patients with serious pulmonary function impairment due to lung disease;
• Uncontrolled systemic disease as judged by the investigator, included uncontrolled hypertension, uncontrolled diabetes, pesence of pleural effusion, pericardial effusion, or ascites that is clinically symptomatic or requires repeated drainage;
• Certain viral infections including active hepatitis B or hepatitis C; known history of positive human immunodeficiency virus (HIV) test or known acquired immunodeficiency syndrome (AIDS); or positive syphilis antibody test;
• Known active tuberculosis;
• Known hypersensitivity to the study drug or any of its components, or severe allergic reactions to other monoclonal antibodies;
• Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
• Pregnant or lactating women;
• Any patient whose condition deteriorates rapidly during the screening process prior to the first dose, such as severe changes in performance status, unstable pain requiring adjustment of analgesic therapy, etc
• Other circumstances that, in the opinion of the investigator, are not appropriate for participation in this study.

Sponsors & Collaborators

• Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.: lead

Study Sites (2)

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, 510060, China

NOT YET RECRUITING

Sun Yat-sen University Cancer Center

Guangzhou, China

RECRUITING

Related Publications (1)

• Hong S, Wang Q, Cheng Y, Luo Y, Qu X, Zhu H, Ding Z, Li X, Wu L, Wang Y, Hu S, Wang E, Liu A, Sun Y, Fan Y, Ye F, Lu K, Fang J, Shen Y, Jin X, Ge J, Zhang L, Fang W. First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial. Nat Med. 2025 Nov;31(11):3654-3661. doi: 10.1038/s41591-025-03883-5. Epub 2025 Aug 19.

  PMID: 40830660 DERIVED

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

18-O-demethylcervinomycin A2; Carboplatin; Cisplatin

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Coordination Complexes; Organic Chemicals; Chlorine Compounds; Inorganic Chemicals; Nitrogen Compounds; Platinum Compounds

Central Study Contacts

XiaoPin Jin

CONTACT

028-67255165; jinxp@kelun.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 24, 2022
• First Posted: April 28, 2022
• Study Start: May 20, 2022
• Primary Completion: August 1, 2024
• Study Completion: April 1, 2026
• Last Updated: December 14, 2023

Record last verified: 2023-12

Locations

CN (2)